Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

89 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

NCT00544557

Ankylosing Spondylitis

COMPLETED

Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

NCT00227227

Ankylosing Spondylitis

COMPLETED

Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis

NCT00421915

Ankylosing Spondylitis

COMPLETED PHASE3

Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

NCT00420238

Ankylosing Spondylitis

COMPLETED PHASE4

Study Evaluating Etanercept in Patients With Ankylosing Spondylitis

NCT00458185

Ankylosing Spondylitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondylitis, Ankylosing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group Enbrel

Enbrel

Intervention Type DRUG

The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enbrel

The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

etanercept

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines
* Patients treated as an outpatient

Exclusion Criteria

* Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®.
* Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localised infections.
* Patients with sepsis or risk of sepsis should not be treated.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No